Acute Radiation Syndrome - Pipeline Insight, 2024

This “Acute Radiation Syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Radiation Syndrome Understanding

Acute Radiation Syndrome: Overview

Acute Radiation Syndrome (ARS) also known as radiation toxicity or radiation sickness is an illness when a person’s whole body or a significant portion of body is exposed to high levels of radiation for a short period of time. The effects of exposure to radiations are nonspecific signs and symptoms severity of symptoms depends on how much radiation was absorbed, the strength of the radiated energy, the time of exposure, and the distance between body and the source of radiation. Treatment of ARS focuses on reducing and treating infections, maintaining hydration, and treating injuries and burns, surgery for patients with life threatening disease. The lower the radiation dose, the more likely it is that the person will recover from ARS.

Acute Radiation Syndrome - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Radiation Syndrome pipeline landscape is provided which includes the disease overview and Acute Radiation Syndrome treatment guidelines. The assessment part of the report embraces, in depth Acute Radiation Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Radiation Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Radiation Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Radiation Syndrome.

Acute Radiation Syndrome Emerging Drugs Chapters

This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Radiation Syndrome Emerging Drugs

STAT-600: Statera Bio Pharma STAT-600 is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from acute radiation syndrome, and as an oncology drug. The drug is in Phase I clinical studies for the treatment of acuteradiationsickness.

PLX-R18: Pluristem Therapeutics PLX-R18 is a placenta-derived allogeneic therapeutic product. The FDA has cleared Pluristem’s Investigational New Drug (IND) application for PLX-R18 in the treatment of ARS. PLX cell therapy was granted an orphan drug designation by the FDA for the treatment of ARS.

Acute Radiation Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Radiation Syndrome

There are approx. 8+ key companies which are developing the therapies for Acute Radiation Syndrome. The companies which have their Acute Radiation Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Statera BioPharma.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Radiation Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Radiation Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.

Acute Radiation Syndrome Report Insights

• Acute Radiation Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Radiation Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Radiation Syndrome drugs?
• How many Acute Radiation Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Radiation Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Radiation Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Radiation Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bolder BioTechnology
• Neumedicines
• Humanetics Corporation
• Statera BioPharma
• Chrysalis BioTherapeutics
• Pluristem Therapeutics
• Meabco
• iNt RONBiotechnology

Key Products

• BBT-015
• HemaMax
• BIO-300
• STAT-600
• TP508
• PLX R18
• BP-C2
• KMRC011